Best Practice Strategies for Intellectual Property Attorneys for the Pharmaceutical, Biotech and Medical Device Industries

Now entering its 5th annual edition, C5’s Life Sciences IP Summit 2018 returns to Munich this October with brand new speakers and a programme which is jam-packed with rich contents and important discussion points designed to help you optimise your patent portfolio.

For this edition, C5 are excited to announce that the conference will also feature legal information and challenge assessments relevant not only to Pharma and Biotech companies, but will also address the legal environment for Medical Devices companies.

NEW FOR 2018:
  • 2 Specialised Streams for Pharma & Biotech and Medical Devices Industries
  • 2 Pre-Conference Workshops
  • Group Panels and Working Roundtables Sessions
  • Women Leaders in Life Sciences IP Roundtable & Cocktail Reception
  • Evening Networking Drinks

Find out more about the conference, agenda, speakers and hot topics…


Join us to benefit from the exclusive insights of key industry leaders such as:

Dr. Jorg Dreyhsig VP Associate General Counsel IP Fresenius Medical Care AG & Co. KGaA
Karine Crepin Global Head of Biologics Patents Sanofi Global IP Department
Fredrik Fredh European Patent Attorney Novartis Pharma AG
Julia Florence Assistant General Counsel (Patents) GlaxoSmithKline
Guido Pontremoli Corporate IP Patent Director Chiesi Farmaceutici
Corinna Sundermann Senior Vice President IP Management Fresenius Kabi Deutschland GmbH
Emilie Frugier Patent Manager NBE Therapeutics AG
Robin Ellis Head of IP Product Development & Strategy Sandoz

Don’t take our word for it though, hear what previous delegates have to say:

  • “The hottest topics were covered by high level speakers and the networking opportunities were great.” – Esteve
  • “Very interesting, size of group was excellent.” – Bayer
  • “Very interactive and great examples of case law.” – Benitec Biopharma
  • “A rewarding experience due to the competent and experienced faculty addressing current complex issues that are of interest to those involved with intellectual property.” – Past attendee